Review of Real-World Implementation Data on Emtricitabine-Tenofovir Disoproxil Fumarate as HIV Pre-exposure Prophylaxis in the United States

Medicine & Life Sciences

• Emtricitabine 100%
• Pre-Exposure Prophylaxis 99%
• Tenofovir 88%
• HIV 48%
• Cost-Benefit Analysis 10%
• Retention in Care 8%
• Unplanned Pregnancy 7%
• Seroconversion 6%
• Centers for Disease Control and Prevention (U.S.) 5%
• Risk-Taking 5%
• United States Food and Drug Administration 5%
• Pharmacists 5%
• Sexually Transmitted Diseases 5%
• Patient Compliance 5%
• Drug Resistance 5%
• Bone Density 5%
• Virus Diseases 4%
• Clinical Trials 3%
• Guidelines 3%
• Kidney 3%
• Pharmaceutical Preparations 2%